We work closely with you to talk through your current skin condition in our free consultations that you can book today
For now, the panels recommendations are just that
The muscle loss, she argues, isn't caused by the medication itself it's caused by inadequate nutrition and inactivity during rapid weight loss
Already training consistently before starting: Patients at our clinic in Doral who see the strongest lean mass response to CJC-1295/Ipamorelin are those who were already training 3 or more times per week before their first injection

Based on the clinical evidence and the patient profiles where the compound appears most applicable, the following characteristics tend to describe good candidates for AOD 9604 evaluation when it is medically supervised: Patients with stubborn localized fat deposits that have not responded to diet and exercise, particularly visceral and lower abdominal fat Patients who cannot tolerate GLP-1 medications due to nausea, gastrointestinal side effects, or contraindications Active patients with reasonable baseline metabolic health who want a targeted lipolytic tool to complement their training and nutrition program Patients already on a peptide protocol who want to add a fat-targeting element to a GHK-Cu, NAD+, or sermorelin stack Patients who are not candidates for stimulant-based fat loss medications due to cardiovascular sensitivity, anxiety, or blood pressure concerns AOD 9604 is not appropriate as a standalone weight loss strategy for patients with significant obesity, insulin resistance, or metabolic syndrome

No, these are medical research compounds and not skincare ingredients